Tag: research

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia

SHREWSBURY, United Kingdom, July 02, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, an AI-native decentralized infrastructure platform, today announced the start of its Final Bonus Phase, following the successful completion of all 15 presale stages and the achievement of a major milestone—$21.1 million raised from a global community of early contributors. This final round offers a fixed price of $0.007125 per LCAI token, providing one last opportunity for participants ahead of the mainnet launch scheduled for July 2025.

SHREWSBURY, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- Lightchain AI, the AI-native blockchain infrastructure platform, has entered its Bonus Round after successfully completing 15 presale stages and raising more than $21.1 million from early supporters. The Bonus Round is now live at a fixed token price of $0.007125, marking the final opportunity for contributors to access Lightchain AI tokens before the mainnet launch scheduled for July 2025.

Mahe, Seychelles, July 01, 2025 (GLOBE NEWSWIRE) -- BitMart Research, the research arm of BitMart Exchange, has released a comprehensive analysis on the resurgence of the Base ecosystem, highlighting its explosive growth, evolving narratives, and rising institutional alignment. As daily active addresses, TVL, and transaction volumes reach new highs, Base is rapidly transitioning from a speculative L2 to a foundational layer for compliant, on-chain financial and content infrastructure. With support from Coinbase’s strategic initiatives and breakout projects like Virtual and Kaito redefining launch dynamics and the attention economy, Base is emerging as a pivotal force in bridging traditional finance and Web3 innovation.

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Zentalis^® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 14,000 shares of the Company’s common stock to one (1) newly hired employee. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).

According to Pixalate’s latest Supply Path Optimization (SPO) research using SupplyChain Object (SCO) data, an estimated $880 million in global web open programmatic ad spend is routed through unauthorized sellers; unauthorized direct seller web traffic saw a 159% higher IVT, including ad fraud

According to Pixalate’s latest Supply Path Optimization (SPO) research using SupplyChain Object (SCO) data, an estimated $3.15 billion in global CTV open programmatic ad spend is routed through unauthorized sellers; 9% of mobile in-app traffic with SCOs marked as ‘complete’ was sold by unauthorized direct sellers

According to Pixalate’s latest Supply Path Optimization (SPO) research using SupplyChain Object (SCO) data, an estimated $652 million in global CTV open programmatic ad spend is routed through unauthorized sellers; 28% of Connected TV (CTV) traffic with SCOs marked as ‘complete’ was sold by unauthorized direct sellers